Results for the quarter ended 31.12.2025
Awaiting price reaction for this filing.
Sangam Health Care Products Ltd reported Q3 FY26 (Oct–Dec 2025) net sales of ₹272.15 lakhs, down from ₹286.65 lakhs in Q3 FY25, a decline of about 5%. For the nine-month period, revenue fell to ₹857.82 lakhs from ₹984.67 lakhs, a drop of nearly 13%. Despite the top-line weakness, the company sharply improved profitability — Q3 net profit rose to ₹19.86 lakhs from ₹10.88 lakhs (up ~83% YoY), and nine-month net profit rose to ₹45.71 lakhs from ₹26.22 lakhs (up ~74% YoY). This was driven by lower raw material and other expenses, which lifted operating margins from about 3.8% to 10.7% quarter-on-quarter. Basic EPS for Q3 stood at ₹0.13 vs ₹0.07 last year. The statutory auditor issued a clean limited review report with no qualifications. The company operates in a single segment — manufacturing and sale of medical disposables and surgical products.
Mixed picture for shareholders — sales are contracting, which is a concern, but strong cost control has boosted margins and profits meaningfully. The market reaction may depend on whether investors focus on the profit beat or the ongoing revenue decline.